Data on Provectus Pharmaceuticals Inc.'s PV-10 to be Presented at the HemOnc TodayMelanoma and Cutaneous Malignancies Conference on March 22, 2013  
3/20/2013 9:44:25 AM

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT,, a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 for metastatic melanoma will be included in a presentation at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on Friday, March 22, 2013 in New York. Dr. Robert H.I. Andtbacka, Assistant Professor of Surgical Oncology, Huntsman Cancer Institute at the University of Utah in Salt Lake City, is scheduled to present during conference session on Local-Regional Therapy. His presentation, “Current Status of Injectable Therapy” begins at 1:55 p.m., EDT. This session will be moderated by Sanjiv S. Agarwala, MD, Principal Investigator for the Phase 2 trial of PV-10, and Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA.